30 related articles for article (PubMed ID: 12784098)
1. Relationship of the
Parkhomenko AA; Zastrozhin MS; Skryabin V; Petukhov AE; Pozdniakov SA; Ivanchenko VA; Zaytsev IA; Bure IV; Bochkov PO; Akmalova KA; Smirnov VV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2023 Dec; 53(4):15-22. PubMed ID: 38076663
[TBL] [Abstract][Full Text] [Related]
2. Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine.
Frederiksen T; Areberg J; Schmidt E; Bjerregaard Stage T; Brøsen K
Clin Pharmacol Ther; 2021 Jan; 109(1):150-159. PubMed ID: 32599653
[TBL] [Abstract][Full Text] [Related]
3. Genetic testing is superior over endogenous pharmacometabolomic markers to predict safety of haloperidol in patients with alcohol-induced psychotic disorder.
Skryabin V; Zastrozhin M; Parkhomenko A; Lauschke VM; Smirnov V; Petukhov A; Pankratenko E; Pozdnyakov S; Koporov S; Denisenko N; Akmalova K; Bryun E; Sychev D
Curr Drug Metab; 2022 Dec; ():. PubMed ID: 36579390
[TBL] [Abstract][Full Text] [Related]
4. Hal, how many types of pelvic pain are there?
Hellman KM; Tu FF
Pain; 2024 Mar; ():. PubMed ID: 38564003
[No Abstract] [Full Text] [Related]
5. Pharmacogenetics in the Treatment of Huntington's Disease: Review and Future Perspectives.
García-González X; Cubo E; Simón-Vicente L; Mariscal N; Alcaraz R; Aguado L; Rivadeneyra-Posadas J; Sanz-Solas A; Saiz-Rodríguez M
J Pers Med; 2023 Feb; 13(3):. PubMed ID: 36983567
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of CYP genotyping in psychiatry.
Spina E; de Leon J
J Neural Transm (Vienna); 2015 Jan; 122(1):5-28. PubMed ID: 25200585
[TBL] [Abstract][Full Text] [Related]
7. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome.
Kato D; Kawanishi C; Kishida I; Furuno T; Suzuki K; Onishi H; Hirayasu Y
Eur J Clin Pharmacol; 2007 Nov; 63(11):991-6. PubMed ID: 17701031
[TBL] [Abstract][Full Text] [Related]
8. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
Sawamura K; Suzuki Y; Someya T
Eur J Clin Pharmacol; 2004 Oct; 60(8):553-7. PubMed ID: 15349705
[TBL] [Abstract][Full Text] [Related]
9. Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?
Chang WH
Psychopharmacology (Berl); 1992; 106(3):289-96. PubMed ID: 1570373
[TBL] [Abstract][Full Text] [Related]
10. [Effect of smoking on pharmacokinetics of antipsychotics].
Shimoda K
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Apr; 24(2):67-70. PubMed ID: 15164612
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population.
Someya T; Shimoda K; Suzuki Y; Sato S; Kawashima Y; Hirokane G; Morita S; Yokono A; Takahashi S
Neuropsychopharmacology; 2003 Aug; 28(8):1501-5. PubMed ID: 12784098
[TBL] [Abstract][Full Text] [Related]
12. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.
Someya T; Suzuki Y; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
Psychiatry Clin Neurosci; 1999 Oct; 53(5):593-7. PubMed ID: 10595685
[TBL] [Abstract][Full Text] [Related]
13. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.
Pan L; Vander Stichele R; Rosseel MT; Berlo JA; De Schepper N; Belpaire FM
Ther Drug Monit; 1999 Oct; 21(5):489-97. PubMed ID: 10519444
[TBL] [Abstract][Full Text] [Related]
14. Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio.
Ohara K; Tanabu S; Ishibashi K; Ikemoto K; Yoshida K; Shibuya H
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):347-50. PubMed ID: 12691769
[TBL] [Abstract][Full Text] [Related]
15. Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio.
Ohara K; Tanabu S; Yoshida K; Ishibashi K; Ikemoto K; Shibuya H
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):945-9. PubMed ID: 14499311
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
